Knockout of αA-crystallin inhibits ocular neovascularization

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 2, 2015, Pages 816-826

  Xu, Qiong ^a   Bai, Yujing ^a   Huang, Lvzhen ^a   Zhou, Peng ^b   Yu, Wenzhen ^a   Zhao, Mingwei ^a  

^a Peking University People s Hospital   (China)

^b Parkway Health Inc ^*  (China)

Author keywords

Choroidal neovascularization; Human umbilical vein endothelial cell; Neovascularization; Oxygeninduced retinopathy; Vascular endothelial growth factor; A crystallin

Indexed keywords

ALPHA CRYSTALLIN; CASPASE 3; CASPASE 9; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CRYAA GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAR WESTERN BLOTTING; FLOW CYTOMETRY; FLUORESCENCE ANGIOGRAPHY; GENE INACTIVATION; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOUSE; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BIOSYNTHESIS; BREEDING; CELL CULTURE; CELL MOTION; DISEASE MODEL; EMBRYOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PREGNANCY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALPHA-CRYSTALLIN A CHAIN; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, KNOCKOUT; PREGNANCY; PREGNANCY, ANIMAL; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL NEOVASCULARIZATION; RNA;

EID: 84922344176     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14734     Document Type: Article

References (60)

1. Hellström A, Smith LEH, Dammann O. Retinopathy of prematurity. Lancet. 2013;382:1445-1457.
2. Sweigard JH, Yanai R, Gaissert P, et al. The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB J. 2014;28:251014-251041.
3. Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27: 331-371.
4. Witmer AN, Vrensen G, Van Noorden CJF, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
5. Liu H, Zhang W, Xu Z, et al. Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci. 2013;54:918-931.
6. Hu Y, Chen Y, Lin M, et al. Pathogenic role of the Wnt signaling pathway activation in laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54:141-154.
7. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150:315-324.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
9. Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121:1740-1747.
10. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171-185.
11. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548.
12. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157-160.
13. Li D, Xie K, Ding G, et al. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett. 2014;346:45-52.
14. Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8:e77117.
15. Ruan Q, Han S, Jiang WG, et al. alphαB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells. Mol Cancer Res. 2011;9:1632-1643.
16. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795.
17. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266-272.
18. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95-113.
19. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist. 2010;15:683-694.
20. Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal antivascular endothelial growth factor injections. Retina. 2011;31: 1449-1469.
21. Scott A, Powner MB, Fruttiger M. Quantification of vascular tortuosity as an early outcome measure in oxygen induced retinopathy (OIR). Exp Eye Res. 2014;120:55-60.
22. Jawad S, Liu B, Li Z, et al. The role of macrophage class a scavenger receptors in a laser-induced murine choroidal neovascularization model. Invest Ophthalmol Vis Sci. 2013; 54:5959-5970.
23. Andley UP. Crystallins in the eye: function and pathology. Prog Retina Eye Res. 2007;26:78-98.
24. Horwitz J. Alpha-crystallin can function as a molecular chaperone. Proc Natl Acad Sci U S A. 1992;10449-10453.
25. Kannan R, Sreekumar PG, Hinton DR. Novel roles for α-crystallins in retinal function and disease. Prog Retin Eye Res. 2012;31:576-604.
26. Rao NA, Saraswathy S, Wu GS, et al. Elevated retina-specific expression of the small heat shock protein, αA-crystallin, is associated with photoreceptor protection in experimental uveitis. Invest Ophthalmol Vis Sci. 2008;49:1161-1171.
27. Xi J, Farjo R, Yoshida S, et al. A comprehensive analysis of the expression of crystallins in mouse retina. Mol Vis. 2003;28: 410-419.
28. Yaung J, Kannan R, Wawrousek EF, et al. Exacerbation of retinal degeneration in the absence of alpha crystallins in an in vivo model of chemically induced hypoxia. Exp Eye Res. 2008; 86:355-365.
29. Fort PE, Freeman WM, Losiewicz MK, et al. The retinal proteome in experimental diabetic retinopathy: up-regulation of crystallins and reversal by systemic and periocular insulin. Mol Cell Proteomics. 2009;8:767-779.
30. Rao NA, Saraswathy S, Pararajasegaram G, et al. Small heat shock protein αA-crystallin prevents photoreceptor degeneration in experimental autoimmune uveitis. PloS One. 2012;7: e33582.
31. Chen P, Ji W, Liu FY, et al. Alpha-crystallins and tumorigenesis. Curr Mol Med. 2012;12:1164-1173.
32. Sinha D, Klise A, Sergeev Y, et al. bA3/A1-Crystallin in astroglial cells regulates retinal vascular remodeling during development. Mol Cell Neurosci. 2008;37:85-95.
33. Zhang C, Gehlbach P, Gongora C, et al. A potential role for band c-crystallins in the vascular remodeling of the eye. Dev Dyn. 2005;234:36-47.
34. Kase S, He S, Sonoda S, et al. αB-crystallin regulation of angiogenesis by modulation of VEGF. Blood. 2010;115:3398-3406.
35. Dimberg A, Rylova S, Dieterich LC, et al. αB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood. 2008;111:2015-2023.
36. Zhu W, Qi X, Ren S, et al. αA-crystallin in the pathogenesis and intervention of experimental murine corneal neovascularization. Exp Eye Res. 2012;98:44-51.
37. Jia C, Zhu W, Ren S, et al. Comparison of genome-wide gene expression in suture-and alkali burn-induced murine corneal neovascularization. Mol Vis. 2011;17:2386.
38. Yu WZ, Li XX, She HC, et al. Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res. 2003;35:239-246.
39. Bai YJ, Huang LZ, Xu XL, et al. Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther. 2012; 342:131-139.
40. Du W, Yu W, Huang L, et al. Ephrin-a4 is involved in retinal neovascularization by regulating the VEGF signaling pathway. Invest Ophthalmol Vis Sci. 2012;53:1990-1998.
41. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
42. Sun Y, Yu W, Huang L, et al. Is asthma related to choroidal neovascularization? PLoS One. 2012;7:e35415.
43. Berdugo M, Bejjani RA, Valamanesh F, et al. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci. 2008;49:1633-1644.
44. Kim C, Yu HG, Sohn J. The anti-angiogenic effect of chlorogenic acid on choroidal neovascularization. Korean J Ophthalmol. 2010;24:163-168.
45. Bloemendal H. Lens proteins. CRC Crit Rev Biochem. 1982; 12:1-38.
46. Kannan R, Santhoshkumar P, Mooney BP, et al. The αA66-80 peptide interacts with soluble a-crystallin and induces its aggregation and precipitation: a contribution to age-related cataract formation. Biochemistry. 2013;28:3638-3650.
47. Laurie KJ, Dave A, Straga T, et al. Identification of a novel oligomerization disrupting mutation in CRYAA associated with congenital cataract in a South Australian family. Hum Mutat. 2013;28:435-438.
48. Kapphahn RJ, Ethen CM, Peters EA, et al. Modified αA crystallin in the retina: altered expression and truncation with aging. Biochemistry. 2003;42:15310-15325.
49. Nakata K, Crabb JW, Hollyfield JG. Crystallin distribution in Bruch’s membrane-choroid complex from AMD and agematched donor eyes. Exp Eye Res. 2005;80:821-826.
50. Saraswathy S, Rao NA. Mitochondrial proteomics in experimental autoimmune uveitis oxidative stress. Invest Ophthalmol Vis Sci. 2009;50:5559-5566.
51. Munemasa Y, Kwong JMK, Caprioli J, et al. The role of αA-and αB-crystallins in the survival of retinal ganglion cells after optic nerve axotomy. Invest Ophthalmol Vis Sci. 2009;50:3869-3875.
52. Kumar PA, Haseeb A, Suryanarayana P, et al. Elevated expression of αA-and αB-crystallins in streptozotocin-induced diabetic rat. Arch Biochem Biophys. 2005;444:77-83.
53. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
54. Le Boeuf F, Houle F, Huot J, et al. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem. 2004;279:39175-39185.
55. Yoon CM, Hong BS, Moon HG, et al. Sphingosine-1-phosphate promotes lymphangiogenesis by stimulating S1P1/Gi/PLC?Ca2þ signaling pathways. Blood. 2008;112:1129-1138.
56. Breslin JW, Pappas PJ, Cerveira JJ, et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol. 2003;284:H92-H100.
57. Pasupuleti N, Matsuyama S, Voss O, et al. The anti-apoptotic function of human αA-crystallin is directly related to its chaperone activity. Cell Death Dis. 2010;1:e31.
58. Xu G, Vogel KS, McMahan CA, et al. BAX and tumor suppressor TRP53 are important in regulating mutagenesis in spermatogenic cells in mice. Biol Reprod. 2010;83:979-987.
59. Fadeel B, Ottosson A, Pervaiz S. Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance. Cell Death Differ. 2008;15:443-452.
60. Al-Azayzih A, Gao F, Goc A, et al. TGFb1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Aktindependent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem Biophys Res Commun. 2012;427:165-170.